CASI PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
CASI PHARMACEUTICALS, INC. (CASIF) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.91% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-05-15
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|
| 2025-12-31 | 3.91% 20-F · filed 2026-05-15 | |
| 2024-12-31 | 4.45% 20-F · filed 2026-05-15 | |
| 2023-12-31 | 4.79% 20-F · filed 2026-05-15 | |
| 2023-05-12 | 5.79% 20-F · filed 2026-05-15 | |
| 2022-12-31 | 2.71% 20-F · filed 2025-03-31 | |
| 2021-12-31 | 1.38% 20-F · filed 2024-03-28 | |
| 2020-12-31 | 1.77% 20-F · filed 2023-04-26 |